{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-222977","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2023-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.071836+00:00","generated_at":"2026-06-11T02:22:25.958456+00:00","sec_items":["2.05","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apellis announces 25% workforce reduction, expects up to $300M cost savings through 2024","bullets":["Reduce workforce by ~225 employees (~25% of total); substantially complete in Q3 2023.","Cost savings of up to $300M through 2024, including $70M+ from workforce reduction and up to $230M from external expenses.","Focus on SYFOVRE U.S. launch and preparation for ex-U.S. launches; reduce EMPAVELI expenses.","Prioritize retina and CNS research; deprioritize siRNA with systemic pegcetacoplan, APL-1030, APL-2006.","Expect $9M-$11M cash costs for restructuring; update on cash runway in Q3 2023 earnings."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-222977","json":"https://secwatch.observer/filing/0001193125-23-222977.json","markdown":"https://secwatch.observer/filing/0001193125-23-222977.md","text":"https://secwatch.observer/filing/0001193125-23-222977.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523222977/0001193125-23-222977-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523222977/d508238d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T02:22:25.958456+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e5b142b252088f61278638793720c9a4cb1e85c5","claim":"Apellis Pharmaceuticals, Inc. announced a restructuring with charges of approximately $9 million to $11 million affecting corporate restructuring includes SYFOVRE launch, EMPAVELI reduction, R&D prioritization (approximately 225 employees, or approximately 25% of its current workforce).","evidence_excerpt":"in workforce will be substantially completed in the third quarter of 2023. As a result of the reduction in workforce, the Company estimates that it will incur approximately $9 million to $11 million in costs, substantially all of which are cash expenditures. These costs are anticipated to be incurred primarily in the second half of 2023. The estimate of costs","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523222977/0001193125-23-222977-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $9 million to $11 million"},{"label":"Affected area","value":"corporate restructuring includes SYFOVRE launch, EMPAVELI reduction, R&D prioritization"},{"label":"Headcount","value":"approximately 225 employees, or approximately 25% of its current workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}